Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216609 | 0.83 | CNR2 (1.00) | CNR2SLC6A4LTA4HKCNH2MAPT | |
| SCHEMBL2736498 | 0.80 | CNR2 (0.73) | CNR2SLC6A4LTA4HKCNH2NPC1 | |
| SCHEMBL216005 | 0.77 | CNR2 (0.58) | CNR2SLC6A4LTA4HKCNH2MAPT | |
| SCHEMBL2736504 | 0.75 | CNR2 (0.73) | CNR2LTA4HKCNH2MAPT | |
| SCHEMBL13991165 | 0.74 | CNR2 (1.00) | CNR2SLC6A4LTA4HKCNH2MAPT | |
| SCHEMBL9499089 | 0.71 | NPC1 (0.52) | CNR2SLC6A4LTA4HKCNH2MAPT | |
| SCHEMBL2736501 | 0.71 | CNR2 (0.74) | CNR2SLC6A4LTA4HKCNH2MAPT | |
| SCHEMBL2736483 | 0.70 | CNR2 (0.71) | CNR2SLC6A4LTA4HKCNH2MAPT | |
| SCHEMBL29818603 | 0.69 | NPC1 (0.54) | CNR2SLC6A4MAPTNPC1 | |
| SCHEMBL28441097 | 0.69 | NPC1 (0.54) | CNR2SLC6A4MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885SLC6A4 2528/4885LTA4H 2119/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885SLC6A4 1020/4885LTA4H 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.